MET and non-small cell lung carcinoma: More recently, two MET kinase-specific inhibitors (capmatinib and tepotinib) have received US Food and Drug Administration (FDA) approval based on overall response rate and duration of response in patients with metastatic NSCLC harbouring MET exon 14 skipping in GEOMETRY mono-1 and VISION trials respectively17, 18.